nu2058 and nu 6027

nu2058 has been researched along with nu 6027 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Garman, EF; Gibson, AE; Golding, BT; Grant, S; Griffin, RJ; Jewsbury, P; Johnson, LN; Lawrie, AM; Newell, DR; Noble, ME; Sausville, EA; Schultz, R; Yu, W	1
Bentley, J; Boyle, FT; Calvert, AH; Cheng, Y; Curtin, NJ; Endicott, JA; Golding, BT; Griffin, RJ; Hardcastle, IR; Jewsbury, P; Mesguiche, V; Newell, DR; Noble, ME; Parsons, RJ; Pratt, DJ; Sayle, KL; Wang, LZ	1
Caldon, EC; Tadesse, S; Tilley, W; Wang, S	1

Reviews

1 review(s) available for nu2058 and nu 6027

Article	Year
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Humans; Neoplasms; Protein Binding; Protein Conformation; Protein Kinase Inhibitors	2019

Other Studies

2 other study(ies) available for nu2058 and nu 6027

Article	Year
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of medicinal chemistry, 2000, Jul-27, Volume: 43, Issue:15 Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydrogen Bonding; Models, Molecular; Protein Serine-Threonine Kinases; Purines; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured	2000
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorganic & medicinal chemistry letters, 2003, Sep-15, Volume: 13, Issue:18 Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyrimidines; Structure-Activity Relationship	2003

Article

Year

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

Journal of medicinal chemistry, 2000, Jul-27, Volume: 43, Issue:15

Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydrogen Bonding; Models, Molecular; Protein Serine-Threonine Kinases; Purines; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured

2000

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

Bioorganic & medicinal chemistry letters, 2003, Sep-15, Volume: 13, Issue:18

Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyrimidines; Structure-Activity Relationship

2003